Advanced Enzyme Technologies reports strong Q1 FY26 growth, highlights global presence

Advanced Enzyme Technologies Ltd. (AETL) announced its investor presentation for an upcoming Pharma and Healthcare conference. The company reported a Q1 FY26 consolidated revenue of ₹1,859 mn, reflecting a 20% year-on-year increase and an 11% quarter-on-quarter growth. EBITDA for Q1 FY26 stood at ₹564 mn, up 10% year-on-year and 24% quarter-on-quarter, with a PAT of ₹404 mn, marking a 16% year-on-year and 51% quarter-on-quarter rise.

The company's full FY25 consolidated revenue from operations reached ₹6,369 mn, with an EBITDA of ₹1,944 mn and PAT of ₹1,340 mn. AETL maintains a strong global presence with 9 manufacturing units (8 in India, 1 in USA) and 7 R&D units (5 in India, 1 in USA, 1 in Germany). The company boasts over 68 enzymes & probiotics, 400+ proprietary products, and serves more than 700 customers worldwide across 45+ countries.

AETL emphasizes its focus on human healthcare & nutrition (64% of revenue), animal healthcare & nutrition (12%), bio-processing food (13%), bio-processing non-food (3%), and specialized manufacturing (8%). The company also highlighted its strong R&D capabilities, including 17 registered patents, over 100 scientists, and 15 food enzyme dossiers filed with EFSA.